- Laurence, D. J. R., *et al.* (1972). *Proceedings of the Royal Society of Medicine*. In Press.
- LoGerfo, P., Krupey, J., and Hansen, H. J. (1971). *New England Journal of Medicine*, 285, 138.
- LoGerfo, P., LoGerfo, F., Herter, F., Barker, H. G., and Hansen, H. J. (1972). *American Journal of Surgery*, 123, 127.
- Martin, F., and Martin, M. S. (1970). *International Journal of Cancer*, 6, 352.
- Moore, T. L., Kupchik, H. Z., Marcon, N., and Zamchek, N. (1971). *American Journal of Digestive Diseases*, 16, 1.
- Order, S. E., Porter, M., and Hellman, S. (1971). *New England Journal of Medicine*, 285, 471.
- Purves, L. R., and Geddes, E. (1972). *Lancet*, 1, 47.

- Reynoso, G., *et al.* (1972). *Journal of the American Medical Association*, 220, 361.
- Tee, D. E. H., Wang, M., and Watkins, J. (1965). *European Journal of Cancer*, 1, 315.
- Thomson, D. M. P., Krupey, J., Freedman, S. O., and Gold, P. (1969). *Proceedings of the National Academy of Sciences*, 64, 161.
- Trouillas, P. (1971). *Lancet*, 2, 552.
- Viza, D., Davies, D. A. L., and Harris, R. (1970). *Nature*, 227, 1249.
- Yashi, A., Matsuura, Y., Carpenter, C. M., and Hyde, L. (1968). *Journal of the National Cancer Institute*, 40, 663.
- Zamchek, N., Moore, T. L., Dhar, P., and Kupchik, H. Z. (1972). *New England Journal of Medicine*, 286, 83.

Carcinoembryonic Antigen in the Urine of Patients with Urothelial Carcinoma

R. R. HALL, D. J. R. LAURENCE, D. DARCY, U. STEVENS, R. JAMES, S. ROBERTS, A. MUNRO NEVILLE

British Medical Journal, 1972, 3, 609-611

Summary

Increased amounts of carcinoembryonic antigen (C.E.A.) or C.E.A.-like material are found in the urine of many patients with transitional cell carcinomas of the bladder, including those presumed to be at an early stage of development. It is suggested that measurement of urinary C.E.A. is of clinical diagnostic value in the detection and follow-up of urothelial carcinomas.

Introduction

In the accompanying paper (Laurence *et al.*, 1972) the radio-immunoassay of the carcinoembryonic antigen (C.E.A.) in plasma is shown to be of clinical value in the diagnosis and follow-up of patients with, in particular, carcinomas of the gastrointestinal tract, bronchus, and breast, although such assays have little or no clinical significance as an initial screening test for cancer in general.

C.E.A. was originally thought to be a specific product of endodermally-derived neoplasms (Gold and Freedman, 1965). Accordingly, in view of the embryological origin of the bladder we have investigated the potential value of urinary C.E.A. measurements for the screening, diagnosis, and follow-up of patients suspected of having urothelial carcinoma.

Subjects and Methods

The C.E.A. content of urine or plasma, or of both, was measured in patients with urothelial (transitional cell) carcinomas, non-urothelial malignant tumours, and various benign, non-urothelial or renal, diseases. All were inpatients or outpatients of the Royal Marsden Hospital. The urinary C.E.A. levels were also measured in healthy subjects aged 16 to 90 years who were members of the staff of the Royal Marsden Hospital or Institute of Cancer Research, or were inpatients of the Royal Hospital,

Chelsea, or the Chelsea Hospital for Women, or who attended a general practitioner's surgery for trivial non-urinary complaints.

Plasma samples were obtained as described previously (Laurence *et al.*, 1972). Urine was collected in 20 ml sterile containers. No special precautions were taken, in that samples were not midstream nor were they taken at any particular time of the day. Each specimen was tested for albumin, glucose, and blood and for infection or bacterial contamination by means of dip-inoculum plates (Oxoid), which were incubated at 37°C for 24 hours. If significant infection (>100,000 organisms/ml) was found the organisms were identified. Specimens were stored thereafter at -70°C until assay.

Urine samples in 1 ml aliquots were dialysed using cellulose acetate (Visking 8/32) tubing for three hours against phosphate-buffered saline pH 7.2, 0.01 M in EDTA. Duplicate (0.2 ml) samples of the undialysable portion were then assayed for their C.E.A. content as described previously (Laurence *et al.*, 1972). The results are expressed as ng of C.E.A. per ml of urine.

Results

MALE SUBJECTS

Analysis of the urinary C.E.A. content of healthy control male subjects yielded a mean level of 14 ng/ml, with a coefficient of variation of 1.22. On this basis 35 ng/ml was chosen as the upper limit of normal in males; 42 of the 46 subjects fell below this level (Table I). None of the four control subjects with raised values had clinical evidence of urinary disease. Examination of the C.E.A. values as a function of age of the control subjects failed to show rising titres with increasing age. Of 30 males with histologically proved active transitional cell carcinomas of the bladder 20 had urinary C.E.A. levels in excess of 35 ng/ml. Fourteen men who had had previously treated carcinomas of the bladder and who at the time of the present study were judged tumour-free cystoscopically and cytologically all had C.E.A. levels within the normal range. Of the seven patients with benign disorders (including peptic ulceration, ulcerative colitis, and urolithiasis) and the 16 with malignant tumours of other systems (including prostate, testis, renal parenchyma, gastrointestinal tract, and skin) only one with colonic diverticulitis and no evidence of urothelial disease had a raised urinary level of C.E.A. Seven of these 16 patients had plasma levels of C.E.A. between 14 ng and 500 ng/ml.

Examination of the high C.E.A. levels given by carcinoma of the bladder according to the clinical stage of the tumour and its

Royal Marsden Hospital and Chester Beatty Research Institute, London S.W.3

R. R. HALL, F.R.C.S., Vandervell Research Fellow
D. J. R. LAURENCE, PH.D., Senior Scientist
D. DARCY, D.Phil., Senior Lecturer
U. STEVENS, Junior Technical Officer
R. JAMES, B.Sc., Junior Technical Officer
S. ROBERTS, Junior Technical Officer
A. MUNRO NEVILLE, M.D., M.R.C.PATH., Clinical Scientist

TABLE I—Urinary C.E.A. Levels in Healthy Subjects and in Association with a Variety of Disorders

	Males					Females				
	Urinary C.E.A. (ng/ml)				Incidence of Positive Assays*	Urinary C.E.A. (ng/ml)				Incidence of Positive Assays*
	<35	35-60	61-100	>100		<35	35-60	61-110	<110	
Normal controls	42	3	1	—	4/46	30	8	4	6	6/48
Carcinoma of bladder .. .	10	5	3	12	20/30	1	1	—	6	6/8
Previous carcinoma of bladder†	14	—	—	—	0/14	2	—	—	—	0/2
Carcinoma of bladder plus infection	—	1	—	10	11/11	—	—	—	3	3/3
Non-urothelial malignant tumours ..	16	—	—	—	0/16	4	3	1	2	2/10
Benign disease .. .	6	1	—	—	1/7	3	—	1	1	1/5
Urinary infection .. .	—	—	—	4	4/4	—	1	—	3	3/4

* Upper limit of normal in males is taken as 35 ng/ml and in females as 110 ng/ml for random urine specimens.

† No clinical evidence of recurrent tumour.

morphological differentiation (Table II) showed that the urinary C.E.A. levels were independent of the size and extent of invasion by the tumour and of the degree of differentiation. Some small superficial (T1) tumours could be associated with as high levels of C.E.A. as large invasive (T4) tumours (Table II).

TABLE II—Urinary C.E.A. Levels in Male Patients as Function of Stage and Grade of Transitional Cell Carcinomas

Urinary C.E.A. (ng/ml):		<35	35-60	61-100	>100
Stage*	T1 .. .	5	1	0	3
	T2 .. .	—	—	—	—
	T3 .. .	3	3	4	4
	T4 .. .	2	1	—	4
Grade†	Well differentiated .. .	1	—	—	2
	Moderately well differentiated ..	3	1	1	4
	Poorly differentiated .. .	3	3	2	2

* U.I.C.C. classification.

† Histological data on eight tumours were not available for personal review and those lesions have been omitted.

FEMALE SUBJECTS

The urinary content of C.E.A. in healthy control females showed a broader distribution of values, with a mean of 47 ng C.E.A./ml and a coefficient of variation of 1.29. This gives an upper limit of normal of 110 ng/ml (Table I); 6 of the 48 control female subjects had higher levels without evidence of urinary disease.

By selecting the type of urinary sample collected it is possible to show that contamination with either vaginal or cervical secretions or both may account for this difference between normal male and female control values. Fifteen female nurses gave random and then midstream specimens of urine; while the random samples contain a range of C.E.A. levels, one of which was over 110 ng/ml, all midstream specimens contained less than 35 ng/ml (Table III). Twenty-six other women with benign non-urothelial disease gave midstream specimens of urine, all of

TABLE III—Urinary C.E.A. levels in Women according to Method of Specimen Collection

Patients	Type of Urine Specimen	Urinary C.E.A. (ng/ml)			
		<35	35-60	61-110	>110
Female nurses {	Random	13	—	1	1
	Midstream	15	—	—	—
	Midstream	16	8	2	—
Females with benign non-urothelial disease {	Catheter	7	—	—	—

which contained less than 110 ng of C.E.A. per ml; seven of them also gave a catheter specimen, the values for which lay below 35 ng/ml (Table III).

The urinary C.E.A. levels in six out of eight women with proved active transitional cell carcinomas of the bladder were in excess of 110 ng/ml (random urine samples) (Table I), and three of these six tumours fell into stage T1. Two patients with successfully treated tumours of the bladder had levels below 35 ng/ml (Table I).

Of the female patients with benign disorders or non-urothelial malignant tumours only one with essential hypertension and two with non-urothelial malignancy had C.E.A. levels in excess of 110 ng/ml (Table I). One patient had a malignant lymphoma which at necropsy was shown to be infiltrating the renal parenchyma, while the other had extensive carcinoma of the cervix to account for the raised level. Both these patients had plasma C.E.A. levels of less than 12.5 ng/ml, while four of the remainder in this group had values between 14 ng and 84 ng/ml.

URINARY CONSTITUENTS AND C.E.A. LEVELS

The presence in urine of contaminating bacteria, irrespective of their numbers or their type, did not influence the measured level of urinary C.E.A. However, eight patients with symptomatic urinary infection (four males and four females) had high levels similar to those found with carcinoma of the bladder (Table I). Urinary concentrates from two of these patients were submitted to Ouchterlony immunodiffusion analyses when a line of identity was obtained with authentic C.E.A. tested against goat anti-C.E.A. sera.

The presence of haematuria or glycosuria does not influence the apparent C.E.A. level. Also 37 female and 10 male control subjects had varying amounts of albuminuria; their range of urinary C.E.A. values fell within the same range as other controls.

COMPARISON OF URINARY AND PLASMA C.E.A. LEVELS

The plasma levels of C.E.A. in this series of patients are shown in Table IV. Seventeen of the 40 male and two of the 10 female patients with proved active bladder carcinomas had plasma levels in excess of 12.5 ng/ml (upper limit of normal); in only one, however, was the value in excess of the critical level of 40 ng/ml (Table IV) (Laurence *et al.*, 1972).

There was no consistent correlation between urinary and plasma C.E.A. levels in the same patient. Of the 34 subjects in whom both values were assayed 7 had raised urine and plasma levels and 15 only high urine values, despite nine patients having T3 and T4 stage tumours. Of the remaining 12 patients 5 had raised plasma levels only and 7 had normal levels in both urine and plasma.

The plasma and urinary C.E.A. levels were available in 15 of the 16 patients with previously treated carcinomas who at the

TABLE IV—Plasma C.E.A. Levels in Male and Female Patients with Bladder Carcinoma

	Plasma C.E.A. (ng/ml)								Incidence of Positive Assays	
	<12.5*				12.5-20					
	M.	F.	M.	F.	M.	F.	M.	F.	M.	F.
Carcinoma of bladder	18	6	7	1	4	-	-	-	11/29	1/7
Carcinoma of bladder plus infection	5	2	5	-	-	1	1	-	6/11	1/3
Previous carcinoma of bladder†	9	-	4	2	-	-	-	-	4/13	2/2

* Level of 12.5 ng C.E.A./ml is taken as upper limit of normal (Laurence *et al.*, 1972).

† No clinical evidence of recurrent disease.

time of the present study were regarded clinically as disease-free. All had normal urinary C.E.A. values (Table I) but six had minimally raised plasma values (Table IV). The future progress of these patients is being carefully followed, as these results may suggest the presence of local tumour undetected by cystoscopy and cytology or occult metastatic disease.

Discussion

This is the first time that C.E.A. or C.E.A.-like material has been demonstrated in the urine of normal subjects and of patients with urothelial carcinomas. Its presence in urine is not too surprising in view of the common endodermal origin of the urinary bladder and gastrointestinal tract from which latter site and whose tumours C.E.A. was first isolated and thought to be "endodermal specific" (Gold and Freedman, 1965). Previous studies have shown that C.E.A. occurs in the plasma and faeces of healthy persons (LoGerfo *et al.*, 1971; Moore *et al.*, 1971; Freed and Taylor, 1972; Laurence *et al.*, 1972) and is raised in association with a variety of malignant tumours and disorders associated with regeneration or inflammation or both (LoGerfo *et al.*, 1971, 1972; Moore *et al.*, 1971; Laurence *et al.*, 1972; Reynoso *et al.*, 1972; Zamchek *et al.*, 1972).

From the results of the present series of urinary C.E.A. assays almost 70% (26/38) of subjects with active bladder carcinomas will be found to have raised levels, while normal levels occur in patients who have had successful removal of the tumour (Table I). In contrast to plasma C.E.A. levels which seem to be raised, particularly after local spread of all types of tumours, high urinary C.E.A. levels occurred in 7 out of 15 examples of T1 bladder carcinomas—that is, showing *in-situ* or early invasive tumours. Consequently, the assay of urinary C.E.A. appears to be clinically useful in the investigation of patients suspected of having urothelial carcinomas, possibly for the screening of the growing "high-risk" population in certain industries and for the detection of persistent or recurrent carcinoma after appropriate treatment.

In this respect, although assay of plasma C.E.A. levels has little to add in the early stages of carcinoma of the bladder, and does not seem to correlate with urinary levels, C.E.A. measure-

ments in plasma and urine are both desirable in the follow-up phases, as plasma values may be raised in the presence of normal urinary levels and so possibly indicate extravascular spread. The more valuable role of urinary C.E.A. for bladder tumours probably is related to the fact that the urine is the immediate environment of the bladder mucosa and its papillary carcinomas. Certainly C.E.A. does not appear in the urine with most non-urothelial tumours even when the plasma level is raised unless such tumours involve the urothelium secondarily or increase the risk of cervical or vaginal contamination.

The possibility of contamination with genital tract secretions in females or in either sex with active urine infection must be borne in mind and excluded before any interpretation of C.E.A. data is made. Both factors can be largely eliminated by routine use of a midstream specimen of urine and its examination for cells and organisms if urinary infection is suspected.

Consequently we conclude from this preliminary data that the estimation of urinary C.E.A. or C.E.A.-like materials represents a further valuable application of this immunoassay in the diagnosis and care of patients suspected of having or with urothelial carcinomas.

We wish to express our gratitude to Professor T. Symington and Mr. David Wallace for their encouragement, and to the many clinicians who allowed patients to be studied in detail. These investigations were supported by the Medical Research Council (Grants 970/656/B and 971/817/B). One of us (R.R.H.) was in receipt of a Gordon Jacobs Research Fellowship.

References

- Freed, D. L. J., and Taylor, G. (1972). *British Medical Journal*, **1**, 85.
- Gold, P., and Freedman, S. O. (1965). *Journal of Experimental Medicine*, **121**, 439.
- Laurence, D. J. R., *et al.* (1972). *British Medical Journal*, same issue
- LoGerfo, P., Krupey, J., and Hansen, H. J. (1971). *New England Journal of Medicine*, **285**, 138.
- LoGerfo, P., LoGerfo, F., Herter, F., Barker, H. G., and Hansen, H. J. (1972). *American Journal of Surgery*, **123**, 127.
- Moore, T. L., Kupchik, H. Z., Marcon, N., and Zamchek, N. (1971). *American Journal of Digestive Diseases*, **16**, 1.
- Reynoso, G., *et al.* (1972). *Journal of the American Medical Association*, **220**, 361.
- Zamchek, N., Moore, T. L., Dhar, P., and Kupchik, H. Z. (1972). *New England Journal of Medicine*, **286**, 83.

Interactions of Benzodiazepines with Warfarin

M. ORME, A. BRECKENRIDGE, R. V. BROOKS

British Medical Journal, 1972, **3**, 611-614

Summary

Administration of nitrazepam (10 mg nightly), diazepam (15 mg/day), and chlorthalidopoxide (15 and 30 mg/day) had no effect on steady-state plasma warfarin concentrations, the plasma half-life of warfarin, or anticoagulant control in patients and it appears safe to prescribe these agents to patients on long-term oral anticoagulants. Urinary excretion of 6 β -hydroxycortisol, however, increased in two out of five patients given chlorthalidopoxide. In rats

pretreatment with chlorthalidopoxide (40 mg/kg for four days) caused stimulation of liver microsomal enzyme activity but neither diazepam nor nitrazepam had this effect.

Introduction

The subject of drug interactions has become very familiar to practising physicians. While a synergistic effect between drugs is widely used in therapeutics more stress is put on the adverse effects of multiple prescribing. This aspect has been widely studied in patients on long-term treatment with oral anticoagulants because such patients are frequently given other agents as part of their treatment and also because both the pharmacological effect and the plasma concentration of the oral anticoagulant can be measured, thus allowing the mechanisms of the interaction to be determined. Pronounced alteration of anticoagulant control in such patients is of obvious clinical importance.

M.R.C. Clinical Pharmacology Research Group and Department of Clinical Pharmacology, Royal Postgraduate Medical School, London W.12

M. ORME, M.B., M.R.C.P., Honorary Senior Registrar
A. BRECKENRIDGE, M.B., M.R.C.P., Lecturer

Department of Chemical Pathology, St. Thomas's Hospital, London S.E.1

R. V. BROOKS, PH.D., D.SC., Reader in Chemical Pathology